The mean corpuscular volume as a prognostic factor for colorectal cancer

Nagai, Hidemasa; Yuasa, Norihiro; Takeuchi, Eiji; Miyake, Hideo; Yoshioka, Yuichiro; Miyata, Kanji

doi:10.1007/s00595-017-1575-x

Cited by 29 publications

(26 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, recent studies found a prognostic implication of MCV in esophageal and liver cancer [19–21]. Our group previously reported that MCV was a prognostic factor for RFS in patients who underwent R0 resection for stage I/II/III CRC, independent of the tumor stage [22]; a low MCV or microcytosis (MCV < 80 fL) was associated with favorable outcomes. Schneider C et al reported that Hb and MCV dropped shortly before the CRC diagnosis, and low MCV was weakly associated with survival of patients with CRC [23].…”

Section: Discussionmentioning

confidence: 97%

Blood cell markers that can predict the long-term outcomes of patients with colorectal cancer

et al. 2019

Self Cite

View full text Add to dashboard Cite

Objectives To identify blood cell markers that predict the long-term outcomes of patients with colorectal cancer. Methods Data from 892 stage II and III colorectal cancer patients who underwent R0 resection were included. We analyzed the correlations of the preoperative blood data, previously reported prognostic indices, and clinicopathologic factors with the long-term outcomes, such as relapse-free survival and overall survival, using univariate and multivariate analyses. Results Multivariate analysis showed that tumor location, stage, mean corpuscular volume, neutrophil-to-lymphocyte ratio, and lymphocyte-to- monocyte ratio were significantly correlated with relapse-free survival. A mean corpuscular volume ≥80.5 fL, neutrophil-to-lymphocyte ratio ≥5.5, and lymphocyte-to- monocyte ratio <3.4 had hazard ratios for disease relapse between 1.39 and 1.93. The cumulative scores of these three factors were aggregated into a laboratory prognostic score, with a maximum score at 6. The relapse-free survival and overall survival were well stratified by a laboratory prognostic score between 0–3 and 4–6, respectively, independent of the stage. Conclusion The mean corpuscular volume, neutrophil-to-lymphocyte ratio, and lymphocyte-to- monocyte ratio can serve as blood cell markers to predict the long-term outcomes of patients who underwent R0 resection for stage II/III colorectal cancer.

show abstract

Section: Discussionmentioning

confidence: 97%

Blood cell markers that can predict the long-term outcomes of patients with colorectal cancer

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mean corpuscular volume (MCV) is a measure of the average volume of red blood cells, and as well as being an indicator of folate and vitamin B12 deficiency, elevated MCV has been linked to the incidence of several cancers. In addition, recent studies have found an association between high MCV and the prognosis of colorectal, esophageal, and liver cancers 3–5 …”

Section: Introductionmentioning

confidence: 99%

Pretreatment High MCV as Adverse Prognostic Marker in Nonanemic Patients with Head and Neck Cancer

et al. 2020

View full text Add to dashboard Cite

Objective Mean corpuscular volume (MCV) has been shown in to be a reliable prognostic marker in other cancers; however, no evidence exists on its use in head and neck squamous cell carcinoma (HNSCC). This study aimed to investigate the association between MCV, hemoglobin, platelet count and albumin concentration, and survival in stage III/IVA‐B HNSCC treated with concurrent chemoradiotherapy. Study Design Retrospective cohort study. Methods In this multicenter retrospective study, we analyzed MCV, platelet count, hemoglobin concentration, and albumin concentration in peripheral blood samples from 260 patients with HNSCC undergoing organ preservation treatment with curative intent at the time of diagnosis. We then analyzed survival outcomes after accounting for confounders using multivariate analysis. Results After adjustment for potential confounders, patients with low hemoglobin had a 3.3‐fold higher risk of death (95% confidence interval [CI]: 2.26‐4.81) than those with normal hemoglobin. Patients with an elevated MCV had a 1.54‐fold higher risk of death (95% CI: 1.06‐2.24), independent of site, stage, and human papillomavirus status. Interestingly, the effect of MCV on overall and progression‐free survival was limited to those with a normal pretreatment hemoglobin. We identified no associations between pretreatment platelet count or albumin concentration and survival. Conclusion These findings suggest that pretreatment anemia and macrocytosis are independent predictors of lower overall and progression‐free survival in HNSCC patients undergoing organ preservation treatment. Level of Evidence III Laryngoscope, 131:E836–E843, 2021

show abstract

“…Findings have shown hematologic parameters, particularly mean corpuscular volume (MCV), to be predictive markers for patients with various cancer entities. Recently, preoperatively elevated MCV, caused by alcohol abuse and acetaldehyde and folate deficiency, was shown to be an independent prognostic factor in ESCC patients 8,9. Whereas ESCC is highly associated with alcohol and nicotine abuse, the association of alcohol consumption and the development of AEG remains unclear 9–14.…”

mentioning

confidence: 99%

High Mean Corpuscular Volume Predicts Poor Outcome for Patients With Gastroesophageal Adenocarcinoma

et al. 2019

View full text Add to dashboard Cite

Background Elevated mean corpuscular volume (MCV) is associated with a diminished prognosis for various tumor entities. This study aimed to evaluate the association between preoperative serum MCV levels and both overall (OS) and disease-free survival (DFS) for patients with resectable adenocarcinomas of the esophagogastric junction (AEG). Methods This study included consecutive patients undergoing surgical resection between 1992 and 2016. Measured preoperative MCV levels were stratified into quintiles and correlated with patients’ survival and clinicopathologic characteristics. Results The study analyzed 314 patients with a median OS of 36.8 months and a median DFS of 20.6 months. The multivariate analysis showed that preoperatively elevated MCV is a significant prognostic factor for OS (hazard ratio [HR], 1.05; 95% confidence interval [CI], 1.03–1.08; P < 0.001) and DFS (HR, 1.05; 95% CI, 1.03–1.08; P < 0.001). In the subgroup analysis of neoadjuvantly treated and untreated patients, MCV remained an independent prognostic factor for OS (HR, 1.08; 95% CI, 1.04–1.12; P < 0.001) and DFS (HR, 1.07; 95% CI, 1.03–1.12; P < 0.001) in both groups. In the univariate analysis, tumor stage and differentiation, adjuvant chemotherapy, MCV, mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) were significantly correlated with diminished OS and DFS. Conclusion Preoperatively elevated MCV is an independent prognostic factor for patients with adenocarcinomas of the esophagus and the gastroesophageal junction.

show abstract

The mean corpuscular volume as a prognostic factor for colorectal cancer

Abstract: MCV was a prognostic factor for the DFS, independent of the tumor stage, in CRC patients who underwent R0 resection.

Cited by 29 publications

References 25 publications

Blood cell markers that can predict the long-term outcomes of patients with colorectal cancer

Blood cell markers that can predict the long-term outcomes of patients with colorectal cancer

Pretreatment High MCV as Adverse Prognostic Marker in Nonanemic Patients with Head and Neck Cancer

High Mean Corpuscular Volume Predicts Poor Outcome for Patients With Gastroesophageal Adenocarcinoma

Contact Info

Product

Resources

About